Clinical trials: Heart Failure and Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo.
- Trial name
- HFpEF (NCT05284617)
- Testing
- HU6
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 686 sites in United States, Argentina and 33 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors generally and empagliflozin specifically have shown cardiovascular benefits in patients with heart failure (HF), but the underlying mechanisms remain unclear.
- Conditions
- Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
- Trial name
- NCT05139472
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Texas Southwestern Medical Center
Cardiovascular Diseases, Heart Diseases
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
- Trial name
- TOPCAT (NCT00094302)
- Testing
- Spironolactone
- Where
- 270 sites in United States, Argentina and 4 more
- Volunteers
- 3,445 people
- Sponsor
- Carelon Research
Heart Failure and Preserved Ejection Fraction, Obesity (Disorder)
OBESE-HFpEF: Towards Preventing Obesity Related HFpEF
Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF). In HFpEF, the heart becomes stiffer.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Obesity (Disorder), Heart Failure
- Trial name
- OBESE-HFpEF (NCT07539766)
- Where
- Netherlands
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
Heart Failure With Preserved Ejection Fraction
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved Ejection Fraction
- Trial name
- NCT04318145
- Testing
- PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Palatin Technologies, Inc
Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.
- Trial name
- NCT06820099
- Testing
- HRS-7535 tablet
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
Patients enrolled into the study will be randomly allocated either to Empagliflozin group or control group. In the Empagliflozin group patients will be receiving standard care + Empagliflozin 10 mg o.d., in the control group…
- Trial name
- NCT03753087
- Testing
- Empagliflozin, Standard care
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure, Heart Failure With Preserved Ejection Fraction
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Acute heart failure (AHF) is defined as rapid onset or rapid worsening of typical signs and symptoms of heart failure (HF) according to the 2016 European Society of Cardiology Guidelines.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- FUTURE-HIT (NCT05204238)
- Testing
- Transthoracic Echocardiography
- Where
- 31 sites in Australia, Belgium and 10 more
- Volunteers
- 998 people
- Sponsor
- University of Siena
Heart Failure
Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction
Background: Heart failure with preserved ejection fraction (HFPEF) is common but not well understood. Electrical dyssynchrony in systolic heart failure is harmful.
- Trial name
- KaRen (NCT00774709)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- French Cardiology Society
Heart Failure, Diastolic, Multicenter Study
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are…
- Trial name
- NCT04602338
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Congestive Heart Failure, Volume Overload
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
The purpose of this study is to analyze the utility of a novel five-point ultrasound as a predictor of volume overload in diverse patients who are admitted with volume overload/congestive heart failure (CHF) exacerbation at…
- Trial name
- BUDS-HF (NCT07096726)
- Testing
- Five-point ultrasound, Standard of care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boston Medical Center
Heart Failure, Physical Exercise
Comparison of the Effect of Two Types of Physical Exercises in Patients With Heart Failure With Preserved Ejection Fraction
Background: Heart failure (HF) is a chronic disease with a very important and increasingly severe social and health impact with a prevalence of 6.8% in Spain.
- Conditions
- Heart Failure, Physical Exercise, Exercise Capacity, Diastolic Function
- Trial name
- ExIC-FEp (NCT05726474)
- Testing
- Combined exercise, High interval training
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- University of Castilla-La Mancha
Heart Failure Low Output, Heart Failure
The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients
This study aims to investigate safety and efficacy of the Occlutech® AFR device in patients with HFrEF (Heart failure with reduced ejection fraction) and HFpEF (Heart failure with preserved ejection fraction)
- Trial name
- PRELIEVE (NCT03030274)
- Testing
- Occlutech AFR device
- Where
- 26 sites in Belgium, Germany and 1 more
- Volunteers
- 106 people
- Sponsor
- Occlutech International AB
Heart Failure
Myocardial Performance at Rest and During Exercise in Heart Failure With Preserved Ejection Fraction
This study is being done to study how well the heart contracts and relaxes during exercise. In addition to traditional measures of heart function, we will use a new computer program that may improve understanding of why people…
- Trial name
- X-HF-SPECKLE (NCT01747785)
- Testing
- Cardiac rehabilitation, Myocardial deformation imaging, Cardiopulmonary exercise test
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University
HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction
Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare…
- Conditions
- HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction, Readmission Rates, Exercise Training
- Trial name
- EMPOWER-HFpEF (NCT07727096)
- Testing
- Exercise-Based Cardiac Rehabilitation, Guideline-Directed Medical Therapy
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
The Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation (EVENT) was designed to examine the hypothesis that, compared with placebo, therapy with the SGLT2 inhibitor enavogliflozin would improve clinical and…
- Trial name
- EVENT (NCT06027307)
- Testing
- Enavogliflozin
- Where
- 5 sites in South Korea
- Volunteers
- 541 people
- Sponsor
- Asan Medical Center